Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Bugianesi

Showing results (251-260 of 293) with videos related to

Pageof 30
Sort By:
Contemporary Clinical Trials|October 12, 2020
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver diseaseTimothy Hardy, Kristy Wonders, Ramy Younes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver DiseaseZobair M Younossi, Janus P Ong, Hirokazu Takahashi, et al.
The Journal of Clinical Investigation|February 10, 2026
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinomaMatteo Mureddu, Serena Pelusi, Oveis Jamialahmadi, et al.
Journal of Hepatology|April 12, 2020
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementMohammed Eslam, Philip N Newsome, Shiv K Sarin, et al.
Journal of Hepatology|June 23, 2025
Impact of first and further decompensation in patients with compensated ACLD due to MASLDGrazia Pennisi, Gabriele Di Maria, Vincent Wai-Sun Wong, et al.
Gut|January 10, 2024
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver diseaseAngelo Armandi, Tiziana Sanavia, Ramy Younes, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 12, 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryZobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Pageof 30

Showing results (251-260 of 293) with videos related to

Sort By:
Pageof 30
Contemporary Clinical Trials|October 12, 2020
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver diseaseTimothy Hardy, Kristy Wonders, Ramy Younes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver DiseaseZobair M Younossi, Janus P Ong, Hirokazu Takahashi, et al.
The Journal of Clinical Investigation|February 10, 2026
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinomaMatteo Mureddu, Serena Pelusi, Oveis Jamialahmadi, et al.
Journal of Hepatology|April 12, 2020
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementMohammed Eslam, Philip N Newsome, Shiv K Sarin, et al.
Journal of Hepatology|June 23, 2025
Impact of first and further decompensation in patients with compensated ACLD due to MASLDGrazia Pennisi, Gabriele Di Maria, Vincent Wai-Sun Wong, et al.
Gut|January 10, 2024
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver diseaseAngelo Armandi, Tiziana Sanavia, Ramy Younes, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 12, 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryZobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Pageof 30